EMEA-003235-PIP01-22 - paediatric investigation plan

xevinapant

Key facts

• Active Substance:
  xevinapant
• Therapeutic area:
  Oncology
• Decision number:
  P/0374/2022
• PIP number:
  EMEA-003235-PIP01-22
• Pharmaceutical form(s):
  Oral solution
• Condition(s) / indication(s):
  Treatment of head and neck epithelial malignant neoplasms
• Route(s) of administration:
  Oral use
• Contact for public enquiries:

  Merck Healthcare KGaA

  Email: [e-mail]; Tel. [phone];

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  09/09/2022

Decision

P/0374/2022: EMA decision of 9 September 2022 on the granting of a product specific waiver for xevinapant (EMEA-003235-PIP01-22)

Reference Number: EMA/705744/2022